Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

17.69
-0.0700-0.39%
Post-market: 17.860.1700+0.96%18:15 EDT
Volume:2.13M
Turnover:37.65M
Market Cap:2.22B
PE:-9.85
High:18.09
Open:17.85
Low:17.46
Close:17.76
Loading ...

Apellis Pharmaceuticals Q4 Product Revenue USD 191.172 Million

THOMSON REUTERS
·
28 Feb

Apellis Pharmaceuticals Q4 Basic EPS USD -0.29

THOMSON REUTERS
·
28 Feb

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
25 Feb

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
24 Feb

Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey
·
24 Feb

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
21 Feb

High Growth Tech Stocks In The United States To Watch

Simply Wall St.
·
21 Feb

Apellis announces EMA validation of Aspaveli indication extension application

TIPRANKS
·
20 Feb

Apellis Pharmaceuticals, Sobi Say EMA Validated Indication Extension Application for Potential Kidney Disease Treatment

MT Newswires Live
·
20 Feb

Apellis and Sobi Announce Ema Validation of Indication Extension Application for Aspaveli® (Pegcetacoplan) for C3g and Primary Ic-Mpgn

THOMSON REUTERS
·
20 Feb

Apellis Pharmaceuticals Inc - Potential U.S. Launch of Pegcetacoplan in Second Half of 2025

THOMSON REUTERS
·
20 Feb

Apellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In January

Insider Monkey
·
19 Feb

Apellis Pharmaceuticals (NASDAQ:APLS investor one-year losses grow to 58% as the stock sheds US$231m this past week

Simply Wall St.
·
13 Feb

Piper Sandler Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)

TIPRANKS
·
10 Feb

Morgan Stanley Reports 7.7% Passive Stake in Apellis Pharmaceuticals Inc as of Dec 31, 2024 - SEC Filing

THOMSON REUTERS
·
04 Feb

Apellis Pharmaceuticals Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
30 Jan

RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
29 Jan

Mizuho Securities Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)

TIPRANKS
·
29 Jan

Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday

MT Newswires Live
·
28 Jan

Apellis Pharmaceuticals' Geographic Atrophy Treatment Gets Approval From Australian Therapeutic Goods Administration

MT Newswires Live
·
28 Jan